Evidence map›Paper›PMID 36952641›Full record

ArticleBlood2023

Macrophage metabolic rewiring improves heme-suppressed efferocytosis and tissue damage in sickle cell disease.

Richa Sharma, Ada Antypiuk, S Zebulon Vance, Deepa Manwani, Quentinn Pearce, James E Cox, Xiuli An, Karina Yazdanbakhsh, Francesca Vinchi

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Dyslipidemia is a metabolic hallmark of acute pain in sickle cell disease.medRxiv : the preprint server for health sciences · 2026
    Article
  3. CD163Biomarker research · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Macrophages in Hematopoiesis and Related Blood Diseases.Genomics, proteomics & bioinformatics · 2025
    Review
  12. Article
  13. Article
  14. Engineering Efferocytosis for Bone Regeneration.Macromolecular bioscience · 2025
    Review
  15. Heme and immunity: The heme oxygenase dichotomy.Journal of inorganic biochemistry · 2025
    Review
  16. Article
  17. Article
  18. Crosstalk Between Sickle Cell Disease and Ferroptosis.International journal of molecular sciences · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Richa SharmaIron Research Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY.
Ada AntypiukIron Research Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY.ORCID 0009-0008-5498-3440
S Zebulon VanceIron Research Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY.
Deepa ManwaniDepartment of Pediatrics, Albert Einstein College of Medicine, New York, NY.
Quentinn PearceDepartment of Biochemistry, University of Utah, Salt Lake City, UT.
James E CoxDepartment of Biochemistry, University of Utah, Salt Lake City, UT.ORCID 0000-0002-5977-2350
Xiuli AnLaboratory of Membrane Biology, New York Blood Center, New York, NY.
Karina YazdanbakhshLaboratory of Complement Biology, New York Blood Center, New York, NY.
Francesca VinchiIron Research Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY.ORCID 0000-0003-1631-8286
New York Blood Center · USUniversity of Utah · USAlbert Einstein College of Medicine · US

Funding

Sickle cell bone marrow niche and regulation of platelet activation and erythropoiesisP01HL149626 · NHLBI · NEW YORK BLOOD CENTER · PI Karina Yazdanbakhsh · 2020 to 2026
$24.4M
Proteomics CoreU54DK110858 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Anna E Beaudin, JAMES Eric COX · 2016 to 2026
$8.6M
Immune Pathophysiology of Sickle Cell DiseaseR35HL161239 · NHLBI · NEW YORK BLOOD CENTER · PI Karina Yazdanbakhsh · 2022 to 2026
$4.5M
Heme toxicity and vaso-occlusion in sickle cell diseaseR01HL114567 · NHLBI · UNIVERSITY OF MINNESOTA · PI VERCELLOTTI, GREGORY M · 2012 to 2020
$4.4M
NHLBI NIH HHS P01 HL149626NHLBI NIH HHS R01 HL114567NHLBI NIH HHS R35 HL161239NIDDK NIH HHS U54 DK110858
6 · The paper itself

Abstract

Sickle cell disease (SCD) is hallmarked by an underlying chronic inflammatory condition, which is contributed by heme-activated proinflammatory macrophages. Although previous studies addressed heme ability to stimulate macrophage inflammatory skewing through Toll-like receptor4 (TLR4)/reactive oxygen species signaling, how heme alters cell functional properties remains unexplored. Macrophage-mediated immune cell recruitment and apoptotic cell (AC) clearance are relevant in the context of SCD, in which tissue damage, cell apoptosis, and inflammation occur owing to vaso-occlusive episodes, hypoxia, and ischemic injury. Here we show that heme strongly alters macrophage functional response to AC damage by exacerbating immune cell recruitment and impairing cell efferocytic capacity. In SCD, heme-driven excessive leukocyte influx and defective efferocytosis contribute to exacerbated tissue damage and sustained inflammation. Mechanistically, these events depend on heme-mediated activation of TLR4 signaling and suppression of the transcription factor proliferator-activated receptor γ (PPARγ) and its coactivator peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α). These changes reduce efferocytic receptor expression and promote mitochondrial remodeling, resulting in a coordinated functional and metabolic reprogramming of macrophages. Overall, this results in limited AC engulfment, impaired metabolic shift to mitochondrial fatty acid β-oxidation, and, ultimately, reduced secretion of the antiinflammatory cytokines interleukin-4 (IL-4) and IL-10, with consequent inhibition of continual efferocytosis, resolution of inflammation, and tissue repair. We further demonstrate that impaired phagocytic capacity is recapitulated by macrophage exposure to plasma of patients with SCD and improved by hemopexin-mediated heme scavenging, PPARγ agonists, or IL-4 exposure through functional and metabolic macrophage rewiring. Our data indicate that therapeutic improvement of heme-altered macrophage functional properties via heme scavenging or PGC1α/PPARγ modulation significantly ameliorates tissue damage associated with SCD pathophysiology.

Indexed as

Anemia, Sickle CellHemeHumansInflammationInterleukin-4MacrophagesPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPAR gammaToll-Like Receptor 4HemeInterleukin-4Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPAR gammaToll-Like Receptor 4

Identifiers

PMID36952641
PMCPMC10315632
OpenAlexW4360608160

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.